Skip to main content
. 2017 May 2;8(40):67017–67028. doi: 10.18632/oncotarget.17549

Figure 3. Cisplatin sensitive and resistant ovarian cancer cells arrest in G2 and M phase following SP-6-27 treatment.

Figure 3

Cisplatin sensitive A2780 or cisplatin resistant cis-A2780 ovarian cancer cells were treated with 0.5μM SP-6-27 or DMSO vehicle control for 24 hours. The cells were evaluated for effects on cell cycle using PI staining and analyzed by flow cytometry using ModFit software. (Ai) Representative cell cycle micrographs of cisplatin sensitive cells depicting G1, S and G2/M cell populations in control and SP-6-27 treated cells. (Aii) Stacked bar graph illustrating the phase distribution of cisplatin sensitive cells in control and SP-6-27 treated groups determined as percentage of the total number of cells in cycle. (Bi) Representative cell cycle micrographs of cisplatin resistant cells depicting G1, S and G2/M cell populations in control and SP-6-27 treated cells. (Bii) Stacked bar graph illustrating the phase distribution of cisplatin resistant cells in control and SP-6-27 treated groups. The data indicates ovarian cancer cell cycle arrest in G2/M phase upon SP-6-27 treatment. Average of three experiments is shown.